Markets:

Overview

News

Currencies

International

Treasuries

Abbott Laboratories (NY:ABT)

109.30 +3.21 (+3.03%)

Official Closing Price Updated: 7:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

52 53 Next >

J&J, Abbott Labs And JPM Among Jim Cramer's Top Picks As Market Shifts Focus From Tech ↗

July 21, 2023

Via Benzinga

Looking At Abbott Laboratories's Recent Unusual Options Activity ↗

July 20, 2023

Via Benzinga

Abbott Laboratories (ABT) Q2 2023 Earnings Call Transcript ↗

July 20, 2023

ABT earnings call for the period ending June 30, 2023.

Via The Motley Fool

Johnson & Johnson's Inflection Point: What it Means for Investors

July 20, 2023

Johnson & Johnson stock and the company show signs of strength and growth while offering value and yield relative to its peer Abbott Laboratories.

Via MarketBeat

Abbott Laboratories Has the Prescription for Higher Share Prices

July 20, 2023

Abbott Laboratories stock is ready to rebound after a year of correction. The decline of COVID is priced into the market, and organic growth is accelerating.

Via MarketBeat

Abbott Stock Edges Higher As Earnings Decline But Still Top Forecasts ↗

July 20, 2023

The company continues to expect some Covid sales this year, but cut its outlook.

Via Investor's Business Daily

Abbott Laboratories's Earnings Outlook ↗

July 19, 2023

Via Benzinga

What's In Store For Abbott Laboratories In Q2 Earnings? ↗

July 15, 2023

Abbott Laboratories is slated to report second-quarter 2023 results on July 20 before the market opens.

Via Talk Markets

Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years ↗

July 10, 2023

Via Benzinga

Tesla Recalls Over 17K EVs Over Camera & Seat Belt Issues, University Research Uncovers Unexpected Fluctuations In ChatGPT Capabilities, Juul Seeks FDA Nod For Next-Generation Vaporizer: Today's Top Stories ↗

July 20, 2023

Benzinga Tesla Recalls More Than 17,000 EVs Over Camera, Seat Belt Issues

Via Benzinga

Abbott Laboratories Clocks Strong Q2 Growth In Underlying Base Business, Reaffirms FY23 Outlook ↗

July 20, 2023

Abbott Laboratories (NYSE: ABT) has reported Q2 FY23 adjusted EPS of $1.08, down 25% Y/Y, beating the consensus of $1.05.

Via Benzinga

Johnson & Johnson, Tesla And 3 Stocks To Watch Heading Into Thursday ↗

July 20, 2023

With U.S. stock futures trading lower this morning on Thursday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Markets Remain Bullish After Dow Rises For Eighth Consecutive Session ↗

July 20, 2023

The CNN Money Fear and Greed index remained in the "Extreme Greed" zone on Wednesday. The Dow Jones gained recorded gains for the eighth straight session on Wednesday, its longest winning streak since...

Via Benzinga

(ABT) - Analyzing Abbott Laboratories's Short Interest ↗

July 03, 2023

Via Benzinga

$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today ↗

June 23, 2023

Via Benzinga

Looking At Abbott Laboratories's Recent Unusual Options Activity ↗

June 20, 2023

Via Benzinga

Earnings Scheduled For July 20, 2023 ↗

July 20, 2023

Companies Reporting Before The Bell • Taiwan Semiconductor (NYSE:TSM) is estimated to report quarterly earnings at $1.08 per share on revenue of $15.49 billion.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

July 06, 2023

Via Benzinga

Here's How Much $1000 Invested In Abbott Laboratories 10 Years Ago Would Be Worth Today ↗

June 16, 2023

Via Benzinga

Looking At Abbott Laboratories's Recent Unusual Options Activity ↗

June 06, 2023

Via Benzinga

Abbott Scores FDA Nod For First Dual-Chamber Leadless Pacemaker To Treat Abnormal, Slow Heart Rhythms ↗

July 05, 2023

The FDA has approved Abbott Laboratories' (NYSE: ABT) AVEIR dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacing system to treat

Via Benzinga

GE HealthCare's Solid Demand And Sensible Margin Targets: Morgan Stanley Sees Potential Upside Despite Street's High Expectations ↗

June 27, 2023

Morgan Stanley analyst Patrick Wood initiated coverage on GE HealthCare Technologies Inc (NASDAQ: GEHC) with an Equal-Weight rating and a

Via Benzinga

Dexcom, A Top 2% Stock, Raises 2025 Outlook Amid 'Rapidly' Expanding Diabetes Market ↗

June 23, 2023

The company makes continuous glucose monitors for patients with diabetes.

Via Investor's Business Daily

Agilent Technologies Stock: Ready to Rise off the Floor

June 21, 2023

Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down (19%) year-to-date. Agilent is a leading global provider.

Via MarketBeat

DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth

June 21, 2023

DexCom's G7 glucose-monitoring solution is driving revenue growth at the company. Analysts expect strong double-digit EPS growth this year and next.

Via MarketBeat

After FDA Rejection, Surmodics' SurVeil Drug-Coated Balloon Scores FDA Approval ↗

June 20, 2023

The FDA has approved Surmodics Inc's (NASDAQ: SRDX) SurVeil drug-coated balloon (DCB), a next-generation device

Via Benzinga

3 Passive Income Stocks to Hold for the Next 20 Years ↗

June 20, 2023

These three stocks are likely to keep increasing their dividends over years or even decades.

Via The Motley Fool

Second Time May Be a Charm: Analyst Is Bullish As Surmodics Resubmits SurVeil DCB Application ↗

June 13, 2023

In an investor presentation, Surmodics Inc (NASDAQ: SRDX) said it submitte

Via Benzinga

2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip ↗

June 04, 2023

Recent troubles won't stop these companies' long-term trajectories.

Via The Motley Fool

Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed' ↗

June 01, 2023

One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug...

Via Benzinga

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

52 53 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.